Globally, by the end of this century low-income cattle farmers in poor countries may face financial loss between $15 to $40 billion annually, due to looming climate change.
Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia, according to a preclinical study by investigators at Weill Cornell Medicine.
Abnormalities in a type of brain cell called astrocytes may play a pivotal role in causing some behavioral symptoms of autism spectrum disorders, according to a preclinical study by Weill Cornell Medicine investigators.
The study suggests that a unique set of regulatory networks controlled by neurons in the gut may be viable targets for future drug therapies to combat chronic inflammatory diseases including asthma, allergy and inflammatory bowel disease.
New research found that establishing complete trauma care programs accessible to 100% of road injury victims could save the lives of 200,000 people annually.
Employers who use technological advancement to reshape workers’ jobs can help improve patient care while improving the work experience of frontline health care workers, Associate Professor Adam Seth Litwin argues in a peer-reviewed commentary.
Some countries use a relatively straightforward cost-effectiveness analysis to decide whether to green light insurance coverage of prescription drugs. That can prevent new drugs from entering the market that would be highly sought after by patients who value costlier care.
Disruption of the circadian clocks that keep the body and its cells entrained to the 24-hour day-night cycle plays a critical role in weight gain, according to a pair of studies by Weill Cornell Medicine investigators.
A new study finds that certain species of bacteria in the gut interact with and help balance levels of dietary cholesterol by using it to create a molecule that plays important roles in human health.
Building on a legacy of groundbreaking advances in medicine and science, Weill Cornell Medicine today launched a $1.5 billion campaign that will harness emerging biomedical innovations to bring exemplary care to patients and create enduring change in medicine.